Summary
A new drug known as donepezil, when taken in time, may help delay the onset of Alzheimer's disease by at least a year, a new clinical study says. When patients notice their memory is slightly faltering, see their doctor, and then begin taking the drug, it appears they may be able to delay symptoms of full blown Alzheimer's disease for a year, the researchers found.
Original source:
http://www.medicalnewstoday.com/medicalnews.php?newsid=22789
Details
In a study of people with mild cognitive impairment (MCI), those who took the drug donepezil were at reduced risk of progressing to a diagnosis of Alzheimer's disease (AD) during the first year of the trial, but by the end of the 3-year study there was no benefit from the drug.
These findings, from the Memory Impairment Study, are the first to suggest than any agent can delay the clinical diagnosis of AD in people with MCI.
The effects of the drug measured in this study "did not provide support for a clear recommendation for the use of donepezil" generally to forestall the diagnosis of AD in people with MCI, the researchers stated in their report, but they did note the potential importance of the findings for some patients.
The data, they said, "could prompt a discussion" between clinicians and patients on the possibility of donepezil therapy in certain cases.
The research was funded in part by the National Institute on Aging (NIA) and was conducted as part of the Alzheimer's Disease Cooperative Study (ADCS), a nationwide clinical trials consortium supported by the NIA, a component of the National Institutes of Health, U.S. Department of Health and Human Services.
As part of the study, the researchers examined the effect of donepezil and vitamin E on delaying diagnosis of AD among a subset of people with MCI with apolipoprotein E-4 (APOE-e4), the only known genetic risk factor for late-onset AD.
While the overall rate of progression to AD was greater in this group, use of donepezil in the APOE-e4 subset was beneficial for up to 36 months in reducing the risk of an AD diagnosis.
"We have not answered the question of whether donepezil reduces the underlying brain changes in
Alzheimer's disease, but now we know that for some people, drug therapy did make a real, clinical difference.
About the author: Mike Adams is a consumer health advocate and award-winning journalist with a passion for teaching people how to improve their health He is a prolific writer and has published thousands of articles, interviews, reports and consumer guides, and he is well known as the creator of popular downloadable preparedness programs on financial collapse, emergency food storage, wilderness survival and home defense skills. Adams is an honest, independent journalist and accepts no money or commissions on the third-party products he writes about or the companies he promotes. In 2010, Adams co-founded NaturalNews.com, a natural health video sharing site that has now grown in popularity. He also founded an environmentally-friendly online retailer called BetterLifeGoods.com that uses retail profits to help support consumer advocacy programs. He's also a noted technology pioneer and founded a software company in 1993 that developed the HTML email newsletter software currently powering the NaturalNews subscriptions. Adams volunteers his time to serve as the executive director of the Consumer Wellness Center, a 501(c)3 non-profit organization, and regularly pursues cycling, nature photography, Capoeira and Pilates. Known as the 'Health Ranger,' Adams' personal health statistics and mission statements are located at www.HealthRanger.org
Have comments on this article? Post them here:
people have commented on this article.
Sunday, May 01, 2005
Email this article to a friend
Share
this article on: 
